Current Shareholders Invest $4.4 Million Into Arrowhead

(Nanowerk News) Arrowhead Research Corporation announced today that it sold 2.5 million units consisting of common stock and common stock purchase warrants in a registered direct offering to investors, the large majority of whom are long-standing Arrowhead shareholders. Gross proceeds will be approximately $4.4 million. Members of Arrowhead's senior management participated in the offering, including CEO Chris Anzalone, who invested over $300,000. Net proceeds from this offering will help fund operations and contribute to Arrowhead's runway to monetization events of its subsidiaries.
"We thought it prudent to increase our liquidity during this time of general market uncertainty," said Arrowhead CEO, Chris Anzalone. "However, we are also sensitive to dilution of our shareholders, so we were careful with the amount of capital raised at this time. We are proud that this offering was completed entirely from current shareholders and senior management."
The non-management investors purchased 2,281,990 units at a per unit price of $1.80. Each unit consisted of one share of common stock and a warrant to purchase an additional share of common stock at an exercise price of $2.00 per share. Members of Arrowhead's senior management purchased 177,596 units at a per unit price of $1.83. The offering was made pursuant to the Company's effective shelf registration statement on Form S-3 (Registration No. 333-148218) previously filed with, and declared effective by, the Securities and Exchange Commission. Pursuant to Rule 424(b) under the Securities Act of 1933, on August 19, 2008 the Company filed with the Securities and Exchange Commission a prospectus and prospectus supplement relating to the registration statement. The offering was made under the foregoing prospectus and prospectus supplement.
The Company may sell up to an additional 3,095,968 units in follow-on offerings at $1.80 per unit (or $1.83 per unit if purchased by a director or officer). The offering is expected to remain ongoing until September 15, 2008 and the Company will make additional SEC filings to report follow-on investments. Such additional securities may be offered only by means of a prospectus supplement.
Copies of the final prospectus supplement and accompanying base prospectus relating to this offering may be obtained at the Securities and Exchange Commission's website at or from the company at 201 South Lake Avenue, Suite 703, Pasadena, CA 91101. This news release is not an offer to sell or the solicitation of an offer to buy the shares of common stock or warrants to purchase shares of common stock or any other securities of the Company.
About Arrowhead Research Corporation
Arrowhead Research Corporation ( is a publicly-traded nanotechnology company commercializing new technologies in the areas of life sciences, electronics, and energy. Arrowhead is building value for shareholders through the progress of majority owned subsidiaries. Currently, Arrowhead has four subsidiaries commercializing nanotech products and applications and investments in two minority-owned subsidiaries.
Source: Arrowhead Research Corporation (press release)
Subscribe to a free copy of one of our daily
Nanowerk Newsletter Email Digests
with a compilation of all of the day's news.
These articles might interest you as well: